CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 54 enrolled
Drug / intervention
Blood transfusionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03727230
NCT03727230N/ACompleted

Single-arm Multicenter Clinical Trial of Blood Transfusion From RhD+ Donors to Asian-type DEL Recipients

Guangzhou Blood Center·interventional·Posted Nov 1, 2018·Updated Mar 21, 2024

In Brief

A clinical study evaluating Blood transfusion for Blood Transfusion and 2 related conditions. Completed, enrolled 54 participants across 10 sites.

Detailed Summary

Red blood cells (RBCs) from Asian-type DEL blood group express very weak RhD antigen and are falsely typed as RhD-negative blood group in routine RhD testing. Until now, Asian-type DEL (D-eluate) patients still be treated as rare RhD-negative patients in the clinic. Previous study from the Asian-type DEL pregnant women with RhD+ fetus showed no occurrence of alloanti-D immunization. This result, however, does not directly be applied for Asian-type DEL patients receiving RhD+ blood transfusions, as lacking of direct evidence regarding the safety and underlying mechanism. In this study, the patients with Asian-type DEL were identified and received RhD+ blood transfusion, then evaluations of any adverse reactions, especially the active follow-up alloantibody test, were prospectively conducted.

Study Details

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedNov 1, 2018
Enrollment StartOct 1, 2016
Primary CompletionOct 9, 2021
Study CompletionNov 30, 2021
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 7.7 years ago

Interventions

Blood transfusionother

Transfusion with RhD+ blood product rather than rare RhD-negative blood to Asian-type DEL recipients